title: Approach to the pediatric patient with Graves' disease: when is definitive therapy warranted?
abstract: Pediatric Graves' disease accounts for 10-15% of thyroid disorders in patients less than 18 yr of age. The onset of symptoms may be insidious and subsequently associated with a delay in diagnosis. Decreased concentration and poor school performance are frequent complaints and can be quite frustrating for the patient and family. Severe ophthalmopathy is uncommon. The diagnosis is established by the findings of an increased heart rate and goiter in the setting of a suppressed TSH and elevated T(3) and/or T(4). The majority of pediatric patients are initially placed on antithyroid medications and maintained on these medications for prolonged periods of time in hopes of achieving remission. Unfortunately, for many children and adolescents remission is unattainable, ultimately occurring in only 15-30% of patients. Several recent studies have suggested that the age of the patient, the degree of thyrotoxicosis at diagnosis, the initial response to therapy, and the level of TSH receptor antibodies serve as reasonable predictors of remission and relapse. However, a consensus on the utility of these markers has not been reached. The present clinical case describes an adolescent with Graves' disease and highlights the negative impact that prolonged medical therapy can have on quality of life and school performance; it reviews pertinent data on the diagnosis, comorbidities, and treatment options; and it identifies gaps in knowledge for when definitive therapy should be pursued. The case serves as a reminder that earlier discussion and decision for definitive therapy should be more commonplace in caring for our pediatric patients with Graves' disease.
authors.affiliation: Department of Pediatrics, Walter Reed Army Medical Center, Washington, D.C. 20307, USA. abauer@usuhs.mil
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Bauer
mesh_terms: D000293:Adolescent; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000502:physiology; D013956:Antithyroid Agents / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D005260:Female; D006042:Goiter / Q000175:diagnosis; D006111:Graves Disease / Q000175:diagnosis / Q000523:psychology / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D018828:Immunoglobulins, Thyroid-Stimulating / Q000502:physiology; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008713:Methimazole / Q000009:adverse effects / Q000627:therapeutic use; D012574:Schools
chemical_list: D019268:Antibodies, Antineutrophil Cytoplasmic; D013956:Antithyroid Agents; D018828:Immunoglobulins, Thyroid-Stimulating; D007457:Iodine Radioisotopes; D008713:Methimazole